A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

NCT06385522 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

NHL
Cutaneous T Cell Lymphoma
Peripheral T-cell Lymphoma

Interventions

BIOLOGICAL: BITR2101

Sponsor

Boston Immune Technologies and Therapeutics